TWO · 7729.TWO
Steminent Biotherapeutics Inc.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
Loading market information…
TWO · 6704.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 06:03 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gwo Xi Stem Cell Applied Technology Co. , Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gwo Xi Stem Cell Applied Technology Co., Ltd. is dedicated to advancing stem cell-based therapies, addressing critical unmet medical needs in patient care. Its product pipeline currently features two pioneering autologous adipose-derived stem cell treatments: GXHPC1, which is in Phase II clinical trials for liver cirrhosis, and GXNPC1, also undergoing Phase II testing, designed for the management of chronic stroke. Further expanding its therapeutic portfolio, the company is advancing GXCPC1, an allogeneic adipose-derived stem cell therapy currently in combined Phase I/II clinical trials for osteoarthritis, alongside GXIPC1, another allogeneic fat-derived stem cell treatment in early-stage Phase I trials for diabetes. Established in 2011, the company maintains its headquarters in Zhubei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$155.00NT$0.00 (0.0%)
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
NT$54.00-NT$1.70 (-3.05%)
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
NT$26.95+NT$0.55 (+2.08%)
Intech Biopharm Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.56% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$43.30-NT$0.30 (-0.69%)
HeXun Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.53% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
